Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma Academic Article uri icon

Overview

MeSH Major

  • Depsipeptides
  • Histone Deacetylase Inhibitors
  • Multiple Myeloma

abstract

  • The results of the current study demonstrate that romidepsin, as a single agent, is unlikely to be associated with a response rate of ≥30% in patients with refractory myeloma, although there was some clinical evidence suggesting a biological effect associated with therapy.

publication date

  • January 15, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3010462

Digital Object Identifier (DOI)

  • 10.1002/cncr.25584

PubMed ID

  • 20862746

Additional Document Info

start page

  • 336

end page

  • 42

volume

  • 117

number

  • 2